£26m for Cystic Fibrosis Drug Trial
Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
Alvotech Advances in Biosimilar Market with Successful AVT03 Study
AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.
Novozymes and Chr. Hansen Complete Merger, Forming Novonesis
Danish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis.
2:1 for new genomic techniques
Following the AGRI Committee of the European Parliament, the lead ENVI Committee has also agreed to relax the rules for the authorisation of NGTs.
Innate immunity merger raises €75m
Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.
Roche jumps ship on AC Immune
<span style="mso-ansi-language:EN-GB" lang="EN-GB">Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with <link https://www.acimmune.com _blank>AC Immune SA</link> after disappointing study results. It has handed the global rights to Crenezumab and […]
Deregulation of new genomic techniques before decision
After the EU Parliament's Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft […]
Amsilk partners with 21st.BIO
AMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins.
Onera Health raises US$32m in Series C round
Sleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.
Spexis sells antibiotics programme to Basilea
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.